Tirzepatide
Dual GIP and GLP-1 receptor agonist used widely in incretin research.
$53.99 – $188.9910 mg · 15 mg · 20 mg · 30 mg · 60 mg
1 vial5-pack −10%10-pack −20%
Metabolic research · Research peptide · Canada
Retatrutide
Investigational triple agonist studied at the GIP, GLP-1 and glucagon receptors.
Labelled amount
Pack
FormLyophilized powder
Molecular weight4731.3 g/mol
CAS2381089-83-2
PurityManufacturer HPLC result stated on the batch COA. Look up a lot →
StorageLyophilized: −20 °C, protected from light. Reconstituted: 2–8 °C.
Supplied asSingle sealed glass vial with printed lot number. Sold per vial or in 5- and 10-packs.
Research topics
Incretin receptor pharmacologyEnergy-balance modelsGlucagon receptor signalling
Research use onlyThis product is a research chemical supplied for in-vitro laboratory use by qualified personnel. It is not approved by Health Canada, is not a drug, and is not for human or veterinary use. Reference values (MW, CAS) are literature values for the base compound; confirm identity and purity against the batch COA.
Related
Full catalogueAlso in metabolic research
Semaglutide
Long-acting GLP-1 receptor agonist and a reference compound in incretin studies.
$40.99 – $96.995 mg · 10 mg · 20 mg
1 vial5-pack −10%10-pack −20%
Cagrilintide
Long-acting amylin analogue studied alone and alongside GLP-1 agonists.
$46.99 – $73.995 mg · 10 mg
1 vial5-pack −10%10-pack −20%
AOD-9604
Modified C-terminal fragment of human growth hormone (hGH 177–191).
$91.9910 mg
1 vial5-pack −10%10-pack −20%